Jim Heil

Jim Heil joined Velocity Sciences in 2014.

He has worked at numerous biotechnology companies including Amgen, Chiron, Gilead Sciences, and SomaLogic. He has a wide variety of knowledge and experience in many aspects of biotechnology.

His career started in the manufacturing of proteins and peptides. He then transitioned into RNA chemistry, surface chemistry, and assay development. His innovations have had significant impacts on enabling proteomics technologies. In addition to his recent proteomics focus, he worked on a team that developed RNA synthesis methods for CRISPR guide RNA that was purchased by Editas Medicine.

Jim has a B.S. from Colorado State University.